Under construction – not a live service
Sign in
Taking peoplePhase 3

Tests azithromycin in adults with advanced HIV disease

Tests a daily pill against placebo in adults with advanced HIV disease.

Plain-language title generated from the registry record
Registry title: Reducing Mortality in Adults With Advanced HIV Disease (REVIVE)

Key facts

Where
Lusaka, ZambiaSee the 3 sites
Phase
Phase 3

Where in Zambia

  • The Center for Infectious Disease Research in Zambia (CIDRZ)- George Clinical Research SiteLusaka, ZambiaNot yet recruiting
  • The Center for Infectious Disease Research in Zambia (CIDRZ)- Matero Clinical Research SiteLusaka, ZambiaNot yet recruiting
  • The Center for Infectious Disease Research in Zambia (CIDRZ)-Chawama Clinical Research Site (CRS)Lusaka, ZambiaNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Population Health Research Institute
Trial code
NCT05580666
Record updated
3 September 2025
Original description
A double blinded, placebo-controlled, multicenter trial to evaluate effectiveness of azithromycin prophylaxis on mortality in advanced HIV.Read full original descriptionShow less

Reducing Mortality in Adults With Advanced HIV Disease, a Double Blinded Randomized Trial

A double blinded, placebo-controlled, multicenter trial to evaluate effectiveness of azithromycin prophylaxis on mortality in advanced HIV.

Inclusion: Age ≥ 18 years; Documented HIV infection; CD4 count criteria:; CD4 count ≤ 100 cells/mm3 within past 4 weeks; or; Documented CD4 nadir ≤ 100 cells/mm3 and complete interruption of ART for ≥ 6 months; or; Documented CD4 count ≤ 100 cells/mm3 if ART-naive; Ability to initiate or re-initiate ART, or switch to an effective ART regimen if failing current therapy, within 4 weeks of enrolment.

Exclusion: Off-label azithromycin prophylaxis or requirement for prolonged (> 7 days) azithromycin (or macrolide) therapy; Severe illness requiring immediate or continued hospitalization (this will be in the judgment of site investigators); Contraindications to azithromycin:; Hypersensitivity to azithromycin, erythromycin, or any macrolide antibiotic; or; Personal or family history of QT-prolongation.

ClinicalTrials.gov NCT05580666